Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.62 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.62 |
| ▸ | HHAT | Q5VTY9 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.53 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.53 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL6822306 | 1.00 | CHRM3 (0.62) | CHRM3CHRM2CHRM1HHATCYP2D6 | |
| Sebacic Acid SCHEMBL4632477 | 0.93 | CHRM3 (0.56) | CHRM3CHRM2CHRM1HHATCYP2D6 | |
| SCHEMBL4250247 | 0.93 | HHAT (0.60) | CHRM3CHRM2CHRM1HHATCYP2D6 | |
| SCHEMBL698295 | 0.93 | HHAT (0.60) | CHRM3CHRM2CHRM1HHATCYP2D6 | |
| SCHEMBL1122195 | 0.93 | HHAT (0.60) | CHRM3CHRM2CHRM1HHATCYP2D6 | |
| SCHEMBL12226990 | 0.93 | HHAT (0.60) | CHRM3CHRM2CHRM1HHATCYP2D6 | |
| Bromide SCHEMBL4631703 | 0.91 | HHAT (0.58) | CHRM3CHRM2CHRM1HHATCYP2D6 | |
| Hydrochloric Acid SCHEMBL8903394 | 0.91 | HHAT (0.58) | CHRM3CHRM2CHRM1HHATCYP2D6 | |
| SCHEMBL27841341 | 0.90 | HHAT (0.62) | CHRM3CHRM2CHRM1HHATCYP2D6 | |
| Oxalic Acid SCHEMBL2995637 | 0.90 | HHAT (0.57) | CHRM3CHRM2CHRM1HHATCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772315-B2 | Pharmaceutical composition for treating overactive bladder | ASTELLAS PHARMA INC. (JP) | 2014-07-08 | — | — | US | claimed |
| US-20130150402-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC. (JP) | 2013-06-13 | — | — | US | claimed |
| US-20120294938-A1 | PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION | Dr. R. Pflefger Chemische Fabrik GmbH (DE) | 2012-11-22 | — | — | US | claimed |
| EP-2216021-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC (JP) | 2012-10-17 | — | — | EP | claimed |
| US-20100240697-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2216021-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | claimed |
| US-20090285891-A1 | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | DR. R. PFLEGER CHEMISCHE FABRIK GMBH (DE) | 2009-11-19 | — | — | US | claimed |
| US-8772315-B2 | Pharmaceutical composition for treating overactive bladder | ASTELLAS PHARMA INC. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130150402-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20120294938-A1 | PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION | Dr. R. Pflefger Chemische Fabrik GmbH (DE) | 2012-11-22 | — | — | US | disclosed |
| EP-2216021-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-8221787-B2 | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | Dr. Robert Pfleger Chemische Fabrik GmbH (DE) | 2012-07-17 | — | — | US | disclosed |
| US-20100240697-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2216021-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
| US-20090285891-A1 | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | DR. R. PFLEGER CHEMISCHE FABRIK GMBH (DE) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150402-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | BPHL, PDE12, UROD | CHRM3 68/4885CHRM2 146/4885CHRM1 589/4885 |
| US-20100240697-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | BPHL, PDE12, UROD | CHRM3 35/4885CHRM2 73/4885CHRM1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.